Searchable abstracts of presentations at key conferences in endocrinology

ea0022p392 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Primary hyperparathyroidism and hyperuricaemia and bone turnover

Broulik Petr

As the major end product of purine metabolism urate is produced by most adults at the rate of 700 mg/day. Although a small proportion of the urate pool may by derived from the diet the greatest amount results from tissue breakdown. Both hyperuricaemia and gout occur with increased frequency in hyperparathyroidism (PHPT). PHPT is associated with a high bone turnover and increased turnover of nucleic acid of cellular origin. Urate metabolism was studied in 106 patients with PHPT...

ea0056p1148 | Thyroid cancer | ECE2018

Prediabetes and type 2 diabetes mellitus and risk of thyroid cancer

Grimmichova Tereza , Matucha Petr

Background: Increasing incidence of thyroid cancer may be attributable to sensitive diagnostic tools as well as changes in exposure to certain environmental factors. Type 2 diabetes mellitus (DM) reaches high prevalence worldwide. DM is a risk factor for many chronic disorders including cardiovascular disease and cancer. Insulin resistance (IR) is a fundamental aspect of the etiology of DM and compensatory hyperinsulinemia could promote cancer growth. The association between D...

ea0073aep100 | Calcium and Bone | ECE2021

Denosumab rebound effect associated with breast cancer recurrence – a coincidence? Case report

Zajickova Katerina , Kasalicky Petr

Denosumab discontinuation leads to loss of bone mineral density (BMD) achieved with treatment and in some patients to multiple vertebral fractures (VFx). Beyond bone, antiresorptive agents such as denosumab may affect breast cancer biology. We report a 69-year-old woman treated with the aromatase inhibitor anastrazole for breast cancer who suffered from five spontaneous vertebral fractures after denosumab cessation. Initially, she received four years of ibandronate followed by...

ea0022p440 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Use of recombinant human thyroid-stimulating hormone (rhTSH) in children and adolescents with differentiated thyroid cancer

Mackova Marketa , Sykorova Pavla , Vlcek Petr

Paediatric thyroid cancer is rare but belongs to the most frequent malignancies in children and its incidence increases. The difference from adult disease subsists in good curability despite of quicker proliferation and earlier development of metastases. Influence of previous radioactivity exposure in the pathogenesis has been proven.For the optimal uptake of radioiodine 131I in the post-operative thyroid remnants it’s necessary to achiev...

ea0022p448 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Conditions and implications of rhTSH application for ablation in treatment of Differentiated thyroid cancer

Sykorova Pavla , Mackova Marketa , Vlcek Petr

A basic tool of the thyroidal cancer treatment is the total thyroidectomy. Immediately after the thyroidectomy, the patients receive a thyroxin. In the case of positive histology after lobectomy, we first indicate the total thyroidectomy. If the tumor is larger than 1 cm or if is a multifocal one, we indicate the ablation of the remnant with I131.Usually, the differentiated thyroid cancer is non-aggressive and we proceed with a standard way of...

ea0022p806 | Thyroid | ECE2010

Scintigraphy 131I-mIBG in patient with positive ret germline mutation for medullary thyroid carcinoma

Vlcek Petr , Zimak Jaroslav , Sykorova Pavla

Purpose: Familial medullary thyroid carcinoma (FMTC) is an autosomal dominant inherited disease, characterized by germ-line mutations in the RET proto-oncogene, mainly in exons 10 and 11, but also in exons 13, 14 and 15. Activating germ-line mutations in the RET proto-oncogene cause the development of familial medullary thyroid carcinoma (FMTC) or medullary thyroid carcinoma (MTC) as a part of multiple endocrine neoplasia type 2 syndrome (MEN2).Me...

ea0014p493 | (1) | ECE2007

Five-year treatment experience with metformin in polycystic ovary syndrome

Petrányi Gyula , Zaoura Maria

In 2002, we introduced metformin as an alternative treatment option of the anti-androgenic contraceptive pill in polycystic ovary syndrome (PCOS). The analysis of our observations is presented here.170 women (age 14–45 y) were diagnosed with PCOS according to the Rotterdam criteria. 88% had acne, 68% hirsutism, 46% irregular menstrual cycles, 39% BMI over 25 kg/m2, 13.5% had apple-type obesity and 4.7% acanthosis nigricans. 104/170 patien...

ea0056p1183 | Thyroid cancer | ECE2018

Pediatric thyroid cancer is associated with more aggressive phenotype and more frequent RET/PTC rearrangements compared with the adult patients

Bendlova Bela , Sykorova Vlasta , Dvorakova Sarka , Vaclavikova Eliska , Pekova Barbora , Katra Rami , Kodetova Daniela , Lastuvka Petr , Plzak Jan , Bavor Petr , Hoch Jiri , Vlcek Petr , Sykorova Pavla , Vcelak Josef

Thyroid cancer in children and adolescents is a rare disease but with an increasing incidence. As in adults, the most prevalent type is papillary thyroid carcinoma (PTC). Our aim was to describe the clinical and genetic comparison between pediatric and adult PTC. We analyzed the cohorts of 73 pediatric PTC (5-18 years, female to male ratio 2.3:1, 10 patients <10 years) and 460 adult PTC patients. DNA and RNA were extracted from cancer tissue samples. DNA was used for seque...

ea0081oc3.6 | Oral Communications 3: Thyroid 1 | ECE2022

RET Fusion Genes in Thyroid Carcinomas

Pekova Barbora , Sykorova Vlasta , Mastnikova Karolina , Vaclavikova Eliska , Moravcova Jitka , Vlcek Petr , Lastuvka Petr , Katra Rami , Bavor Petr , Kodetova Daniela , Chovanec Martin , Drozenova Jana , Astl Jaromir , Hrabal Petr , Vcelak Josef , Bendlova Bela

Objective: RET fusion genes are known driver mutation in thyroid cancer and have been described mainly in pediatric thyroid carcinomas, in which they represent the most common genetic alteration. In large cohorts of adult patients, RET fusions have not yet been well characterized. The aims of this study were to identify RET fusion-positive thyroid tumors in a cohort of different types of thyroid carcinomas and to correlate them with clinical and hist...

ea0084op-07-35 | Oral Session 7: Thyroid Cancer Basic | ETA2022

RET fusion genes in a large cohort of papillary thyroid carcinomas

Pekova Barbora , Sykorova Vlasta , Mastnikova Karolina , Vaclavikova Eliska , Moravcova Jitka , Vlcek Petr , Katra Rami , Lastuvka Petr , Bavor Petr , Kodetova Daniela , Chovanec Martin , Drozenova Jana , Astl Jaromir , Hrabal Petr , Vcelak Josef , Bendlova Bela

Objectives: RET fusion genes are known driver mutations in papillary thyroid carcinomas (PTCs) and have been described mainly in pediatric PTCs, in which they represent the most common genetic alteration. The aims of this study were to identify RET fusion genes in PTCs (from pediatric as well as adult patients), to correlate them with clinical and histopathological features and to determine the prognostic significance of RET fusion genes based on lon...